Company News: Page (1) of 1 - 01/17/18 Email this story to a friend. email article Print this page (Article printing at page facebook

Fitscript Launches Viable Alternative To Pharmaceutical Management of Type 2 Diabetes

  (January 17, 2018)
Fitscript Launches Viable Alternative To Pharmaceutical Management of Type 2 Diabetes

Fitscript, LLC, a company helping people living with diabetes, today announced the launch of GlucoseZone™, the first digital exercise solution for people living with diabetes. The GlucoseZone app is now available for download for iOS or Android devices.

More than 100 million Americans are living with or are at high risk for diabetes, and nearly every one of them is advised by their physician to begin an exercise program. However, for those living with diabetes, exercise is a fundamentally different process, beginning with the need to test blood sugar.

GlucoseZone is the first digital exercise solution that offers exercise guidance based on the user's real-time glucose levels and other diabetes metrics, including data pulled from wearable devices. The patented GlucoseZone program enables doctors to prescribe exercise programs for diabetics to improve A1c achieve weight loss and halt the progression of the disease.

Charlie O'Connell, founder and person living with type 1 diabetes, developed the idea for GlucoseZone from his own need to manage his disease and upon discovering that there were virtually no specific exercise resources available for people living with diabetes. The GlucoseZone program provides an innovative solution to addressing the dangerous complications diabetics encounter when exercising without proper and safe guidance and instruction.

“GlucoseZone grew out of my frustration with the lack of guidance and support available to me" said O'Connell. “Now, with support from a phenomenal team of diabetes experts, fitness professionals, and digital engineers, Fitscript is able to bring to the global diabetes community a solution, accessible via smartphone, to help millions of people like me get control of their diabetes, lower their cost of treatment and take back control of their lives."

The GlucoseZone program represents a viable alternative to pharmaceutical management at every therapeutic stage of type 2 diabetes and presents a radical challenge to the cost assumptions of diabetes care. The annual cost of GlucoseZone is 1/100th of the annual cost of the GLP1-RA pharmaceutical therapies.

The patented GlucoseZone platform offers users content based on their individual and real-time diabetes metrics, providing end users with instruction from fitness and diabetes professionals from around the world that best matches their individual, real-time needs. Users can download the GlucoseZone app, available for iOS or Android devices, and sign up for a free seven-day trial.

Within the application, users can access features such as goal-oriented A1c reduction and weight-loss programs, daily live interactive workouts, on-demand educational content and much more.

GlucoseZone is a clinically validated program proven to help patients achieve lower A1c results and weight loss, halt the pharmaceutical therapeutic progression of diabetes and, in many cases, reduce medication usage and reliance for patients living with diabetes.    
For more information, visit

About Fitscript, LLC:
Created in 2012, Fitscript LLC was founded to help people living with diabetes meet the exercise requirement for safely and effectively reducing, reversing and controlling their diabetes. Fitscript's patented, proprietary GlucoseZone program, now with more than 900,000 users, is the first-ever digital exercise solution for diabetics that helps improve their A1c levels and achieve weight loss based on real-time glucose levels. The all-new GlucoseZone app contains live and on-demand exercise solutions, interactive workouts, diabetes discussions and much more. The app is currently available on iOS and Android.

Read the full story at

Page: 1

Related Keywords:


Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved